The purpose of this study is to investigate advanced metastatic colorectal cancer, ovarian cancer, renal cancer, and pancreatic cancer. This study evaluates an investigational medication administered orally to see if it is safe and can increase arginine levels or has anti-tumor activity.
The study focuses on evaluating the safety and tolerability of the investigational medication. It assesses whether the medication can restore or enhance the body's response to immunotherapy in a general way.
- Who can participate: Participants must be 18 years or older with advanced metastatic colorectal, renal, pancreatic, or recurrent serous ovarian cancer. They must have an ECOG performance status of 0-1 and have received at least one line of systemic cancer therapy.
- Study details: Participants will take the investigational medication orally. The study will evaluate its effects on tumor response and safety. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last up to 6 months.
How understandable was the trial content above?
Hard to understand
Easy to understand